机译:免疫检查点延迟,免疫原性化疗或IFN-α阻断促进了溶瘤病毒疗法的局部和俯视效应
Transgene SA Illkirch Graffenstaden France;
GRCC Inst Cancerol Villejuif France;
Transgene SA Illkirch Graffenstaden France;
Transgene SA Illkirch Graffenstaden France;
Transgene SA Illkirch Graffenstaden France;
Transgene SA Illkirch Graffenstaden France;
Transgene SA Illkirch Graffenstaden France;
Transgene SA Illkirch Graffenstaden France;
Ctr Rech Cordeliers U1138 INSERM Paris France;
GRCC Inst Cancerol Villejuif France;
Gustave Roussy INSERM U1015 DITEP Villejuif France;
GRCC Inst Cancerol Villejuif France;
Ctr Rech Cordeliers U1138 INSERM Paris France;
GRCC Inst Cancerol Villejuif France;
机译:免疫检查点延迟,免疫原性化疗或IFN-α阻断促进了溶瘤病毒疗法的局部和俯视效应
机译:转移力量平衡?溶瘤病毒疗法与免疫检查点封锁相结合治疗胶质母细胞瘤
机译:克服溶血病毒疗法与HDAC抑制剂和免疫检查点封锁的障碍
机译:协同经皮免疫疗法可通过阻断PD1和IDO增强抗肿瘤免疫反应
机译:肿瘤干扰素信号启动并维持免疫检查站封锁的多基因抗药性计划
机译:局部溶瘤病毒疗法会发炎远处的肿瘤并与免疫检查点封锁协同作用导致全身性肿瘤排斥
机译:免疫检查点梗阻,免疫原性化疗或IFN-α阻断促进了溶瘤病毒的局部和俯视效应